Navigation Links
Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition
Date:1/15/2014

Rochester, NY (PRWEB) January 15, 2014

The Microcompetition with Foreign DNA theory explains how latent viruses can cause a major disease. One of these latent viruses is the Epstein Barr Virus (EBV), and one of these diseases is rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease that destroys the body’s joints. As predicted by the theory, a study found that RA patients have high concentrations of EBV DNA in their bodies (1).

What is Microcompetition?

Dr. Hanan Polansky discovered that foreign DNA fragments, called N-boxes, cause most major diseases. When the foreign N-boxes belong to a virus, Microcompetition between the viral DNA and the human DNA can lead to disease. As predicted by Dr. Hanan Polansky, many studies found fragments of DNA that belong to these viruses in many diseased tissues, such as tumors, clogged arteries (arterial plaque), and specifically arthritic joints.

Dr. Hanan Polansky's discovery has important implications. It suggests that medicines can cure and even prevent major diseases, such as rheumatoid arthritis, by targeting the foreign DNA fragments in the human body.

As predicted by the Microcompetition theory, the study on EBV and RA showed that patients with rheumatoid arthritis have high numbers of EBV. “Research has revealed increased viral load, high titers of EBV-directed antibodies, and decreased cell-mediated
control of EBV in RA patients compared to healthy controls (1).”

What is rheumatoid arthritis?

Rheumatoid arthritis (RA) is a chronic inflammatory disease that destroys the body’s joints. The disease “causes premature mortality, disability and compromised quality of life (3).” In addition, study authors wrote that RA “prevalence in women is twofold to fourfold that in men. RA has enormous personal, social, and economic impact; women with RA have overall mortality rates 2.3-fold those in age-matched controls… (2).”

The currently accepted view by the medical community says that there is no known cure for RA.

The CBCD believes that the medical community should learn more about Microcompetition. In addition, the CBCD believes that interrupting the process of Microcompetition, as described by Dr. Hanan Polansky in his ground-breaking book, “Microcompetition with Foreign DNA and the Origin of Chronic Disease,” should be the basis for new therapies targeting RA.

To learn more about Dr. Hanan Polansky’s research and the Theory of Microcompetition with Foreign DNA, visit: http://www.cbcd.net.

Reference:

(1) Epstein-Barr Virus in Systemic Autoimmune Diseases. Published on August 24, 2013.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3766599/#__ffn_sectitle

(2) Epstein–Barr virus and rheumatoid arthritis: is there a link? Published on January 16, 2013
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1526553/

(3) CDC - Rheumatoid Arthritis. Last Updated on November 19, 2012.
http://www.cdc.gov/arthritis/basics/rheumatoid.htm

(4) Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published on August 12, 2013.
     http://gene-eden-kill-virus.com/PP_Gene-Eden-VIR-is-Antiviral.pdf

polyDNA is a biotechnology company that develops dietary supplements using the unique scientific method developed by Dr. Hanan Polansky, which is based on Computer Intuition.

In addition to his unique scientific method, Dr. Polansky published the highly acclaimed scientific discovery, called Microcompetition with Foreign DNA. The discovery explains how foreign DNA fragments, and specifically, DNA of latent viruses, cause most major diseases.

polyDNA developed Gene-Eden-VIR , an antiviral natural remedy that helps the immune system kill latent viruses.

Read the full story at http://www.prweb.com/releases/2014/01/prweb11487598.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Breaking Study: ICU Medicals Tego® Needlefree Connector Proves More Cost Effective Than Traditional Central Venous Catheter Locks
2. Nature Materials study: Graphene invisible to water
3. New Study: Health Professionals Support Biotechnologys Use In Food Products And Sustainable Farming
4. Nature Materials study: Boosting heat transfer with nanoglue
5. RPCI-Led Study: FAK Inhibitor Proves Effective Against Brain Tumors in Preclinical Studies
6. Study: Brain Imaging After Mild Head Injury/Concussion Can Show Lesions
7. New Study: Valtrex (Valacyclovir) Side Effects Target the Brain; polyDNA Suggests a Natural Herpes Remedy
8. Study: FOLFIRINOX Followed by Chemoradiation Shows Substantial Activity in Locally Advanced Pancreatic Cancer
9. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
10. Technical Study: Gilead Sciences Inc., Halozyme Therapeutics Inc., NPS Pharmaceuticals Inc., and InterMune Inc.
11. Study: Higher Hepatitis C Infection During Acupuncture in Asian Americans; polyDNA Recommends That Doctors Prescribe Gene-Eden-VIR against HCV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network ... Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is ... projects are designed, built and brought to market. , The Design Lab is ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
(Date:6/23/2016)... 22, 2016  Amgen (NASDAQ: AMGN ) ... QB3@953 life sciences incubator to accelerate the development ... laboratory space at QB3@953 was created to help high-potential ... for many early stage organizations - access to laboratory ... Amgen launched two "Amgen Golden Ticket" awards, providing each ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/15/2016)... DUBLIN , April 15, 2016 ... of the,  "Global Gait Biometrics Market 2016-2020,"  report ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait ... CAGR of 13.98% during the period 2016-2020. ... movement angles, which can be used to compute ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):